Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/75718
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBenchalak Maneetonen_US
dc.contributor.authorSubsai Kongsaengdaoen_US
dc.contributor.authorNarong Maneetonen_US
dc.contributor.authorSurinporn Likhitsathianen_US
dc.contributor.authorPakapan Woottiluken_US
dc.contributor.authorSuttipong Kawilapaten_US
dc.contributor.authorManit Srisurapanonten_US
dc.date.accessioned2022-10-16T07:02:10Z-
dc.date.available2022-10-16T07:02:10Z-
dc.date.issued2022-10-01en_US
dc.identifier.issn18756190en_US
dc.identifier.issn1570159Xen_US
dc.identifier.other2-s2.0-85137380127en_US
dc.identifier.other10.2174/1570159X20666220507024219en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85137380127&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/75718-
dc.description.abstractBackground: Although a previous review illustrated the efficacy of melatonin receptor agonists (MRAs) in preventing delirium, some recent randomized controlled trials (RCTs) did not confirm these effects. Objectives: This study systematically reviewed the efficacy, acceptability, and tolerability of MRAs for delirium prevention. Materials and Methods: We searched electronic databases, including Scopus, PubMed, CINAHL, and Controlled Trials Register, from their inception to February 20, 2022. The primary efficacy outcome was delirium incidence rate after MRA administration; relative risks (RRs), overall discon-tinuation, and discontinuation due to adverse events are also presented. Results: The overall pooled incidence rates of delirium in MRA-treated and placebo-treated groups were significantly different with RR (95% CI)=0.66(0.52, 0.84, ), I2=59%. Similarly, the incidence rate was significantly lower in the melatonin-treated group than in the placebo-treated group [RR (95% CI) =0.65 (0.49, 0.88), I2=65%]. Unfortunately, incidence rates were not significantly different between ramelteon-treated and placebo-treated groups [RR (95% CI) =0.67 (0.42, 1.08), I2=50%]. The pooled incidence rate of delirium in either melatonin or ramelteon-treated groups was not significantly different from the placebo-treated group in elderly patients. The pooled incidence rate of delirium was significantly lower in the melatonin-treated group than in the benzodiazepine-treated group. Conclusion: Based on this review, melatonin could prevent delirium with a small effect size. How-ever, ramelteon did not show efficacy in preventing delirium. Additionally, neither melatonin nor ramelteon individually showed effectiveness in preventing delirium in elderly patients. Therefore, using MRAs to prevent delirium in clinical practice should be cautious. However, future well-defined and large sample size studies could verify these findings.en_US
dc.subjectMedicineen_US
dc.subjectNeuroscienceen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleMelatonin Receptor Agonists for the Prevention of Delirium: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trialsen_US
dc.typeJournalen_US
article.title.sourcetitleCurrent Neuropharmacologyen_US
article.volume20en_US
article.stream.affiliationsFaculty of Medicine, Chiang Mai Universityen_US
article.stream.affiliationsRangsit Universityen_US
article.stream.affiliationsRajavithi Hospitalen_US
article.stream.affiliationsChiang Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.